Multiple Sclerosis

The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.

Latest News

covid-19 vaccine | Image credit: Leigh Prather - stock.adobe.com
Evaluating COVID-19 Vaccination Safety in Multiple Sclerosis

December 1st 2024

Researchers review the safety, efficacy, and considerations for COVID-19 vaccination in multiple sclerosis patients, especially those on disease-modifying therapies, affirming the vaccine's overall benefit in reducing severe COVID-19 risks without significantly increasing MS relapse rates.

3d illustration of a b cell-sebastianlaulitzki-stock.adobe.com.jpeg
sGFAP May Predict Progression Independent of Relapse in BCDT-Treated MS

November 29th 2024

Word Biomarkers next to a DNA strand | Image credit: iQoncept - stock.adobe.com
Researchers Outline Promising Biomarkers Throughout Course of MS

November 26th 2024

BMI - Olivier Le Moal
Study Finds Obesity May Worsen Multiple Sclerosis: Genetic Analysis Points to Causal Link

November 21st 2024

Doctor examining MRI images of multiple sclerosis MS | Image Credit: © New Africa - stock.adobe.com
Lesion Repair, Damage Processes Correlate With MS Disease Characteristics

November 11th 2024

Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain key insights into managing and understanding this condition.

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain valuable insights into managing and understanding this complex condition.
Continuing Medical Education
View All
December 5th 2024

Assessing the Treatment Landscape for Multiple Sclerosis to Better Individualize Care

1.5 Credits / Neurology
December 5th 2024

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases
December 5th 2024

The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of Early Intervention, Patient-Centered Care, and Disease-Modifying Therapies in Slowing Disease Progression

1.0 Credit / Neurology
December 5th 2024

Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis

1.0 Credit / Immunology, Neurology
December 5th 2024

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

More News

One in 5 Patients With MS Don't Adhere to Oral DMDs
July 24th 2020

One in 5 Patients With MS Don't Adhere to Oral DMDs

Jaime Rosenberg
The researchers noted that these results can help inform therapeutic decision making and identify opportunities to address barriers to disease-modifying drug (DMD) adherence, which not only improves clinical outcomes but also reaps benefits when it comes to health care costs.
Social Media May Benefit Patients With MS-Associated Depression
July 19th 2020

Social Media May Benefit Patients With MS-Associated Depression

Skylar Jeremias
By delivering helpful information and fostering online communities, social media may provide rehabilitation and psychological benefits for patients with multiple sclerosis (MS) who have depression, according to the results of a recent Iranian study.
In MS, Leg Function Declines More Rapidly Than Hand Function, Study Finds
July 18th 2020

In MS, Leg Function Declines More Rapidly Than Hand Function, Study Finds

Jared Kaltwasser
A new study suggests patients with multiple sclerosis (MS) will see their ability to walk decline more rapidly than their hand function.
More Research Needed on Effects of MS in Women, Authors Say
July 17th 2020

More Research Needed on Effects of MS in Women, Authors Say

Mary Caffrey
The review article highlights the many ways that multiple sclerosis (MS) affects women over the lifespan, from pregnancy to childbirth to menopause and beyond—and how both research and clinical practice fall short in meeting their needs.
Patients With Multiple Sclerosis Miss More Work Even Before Diagnosis, Study Finds
July 11th 2020

Patients With Multiple Sclerosis Miss More Work Even Before Diagnosis, Study Finds

Jared Kaltwasser
New research sheds light on how multiple sclerosis affects the work lives of people with the disease. The data show that these patients face higher risks of missed work, even for reasons not directly linked to the disease.
Patients With MS Want to Discuss Costs of Care, but Often Do Not
July 10th 2020

Patients With MS Want to Discuss Costs of Care, but Often Do Not

Jared Kaltwasser
A new study suggests that people living with multiple sclerosis (MS) are often concerned about the costs of their care, but they do not always raise the concern with their doctor.
Determining If Patient Attitudes Impact Adherence in Different Groups of Patients With MS
July 3rd 2020

Determining If Patient Attitudes Impact Adherence in Different Groups of Patients With MS

Allison Inserro
A study from Germany asked patients with multiple sclerosis (MS) about beliefs regarding immune treatments as well as their illness perceptions. Researchers sought to assess these beliefs to test the idea that they are closely connected to adherence behavior.
Defining Transitional MS Remains a Tricky, but Important, Problem
July 2nd 2020

Defining Transitional MS Remains a Tricky, but Important, Problem

Jared Kaltwasser
Most patients who have multiple sclerosis (MS) begin with a relapsing-remitting phase and eventually transition to a secondary progressive phase. In between is believed to be a “transitional” phase, but scientists have yet to discover how to clearly identify patients in transition.
No Link Between Use of DMT, COVID-19 Severity in Patients With MS, Study Finds
June 26th 2020

No Link Between Use of DMT, COVID-19 Severity in Patients With MS, Study Finds

Allison Inserro
The use of disease-modifying therapy (DMT) was associated with a lower risk of hospitalization for patients with coronavirus disease 2019 (COVID-19), and neurological disability, age, and obesity were independent risk factors for more severe cases of infection for patients with multiple sclerosis (MS).
Disability Accumulation in Multiple Sclerosis Is Independent of Relapses
June 22nd 2020

Disability Accumulation in Multiple Sclerosis Is Independent of Relapses

Rachel Lutz
The study authors tested the risk-reducing effects of ocrelizumab compared with interferon β-1a for treatment of multiple sclerosis disability accumulation, with ocrelizumab showing better results in lowering disability accumulation scores.
Is Stress Cardiomyopathy a Sign of Multiple Sclerosis?
June 20th 2020

Is Stress Cardiomyopathy a Sign of Multiple Sclerosis?

Jared Kaltwasser
A new case report highlights the potential links between certain acute cardiac issues and the early stages of multiple sclerosis.
Can Certain Proteins Be Linked to Disease Severity in Multiple Sclerosis?
June 18th 2020

Can Certain Proteins Be Linked to Disease Severity in Multiple Sclerosis?

Allison Inserro
The authors said it was the first study to try and link these 2 central nervous system biomarkers to disease severity in multiple sclerosis.
Bristol Myers Squibb Launches Ozanimod (Zeposia) for RMS
June 3rd 2020

Bristol Myers Squibb Launches Ozanimod (Zeposia) for RMS

Gianna Melillo
Bristol Myers Squibb announced the commercial launch of Zeposia (ozanimod) for relapsing multiple sclerosis (RMS). The oral treatment is the first and only approved sphingosine-1-phosphate receptor modulator with no genetic test or first dose observation at initiation.
Dimethyl Fumarate Safe, Effective Against Relapsing-Remitting MS in New Long-term Results
May 28th 2020

Dimethyl Fumarate Safe, Effective Against Relapsing-Remitting MS in New Long-term Results

Jared Kaltwasser
A new study that looks at the long-term effects of dimethyl fumarate finds the therapy is safe and effective in patients with relapsing-remitting multiple sclerosis who have taken the therapy for approximately a decade.
MS Spending Spiked Over the Past Decade as Costly DMTs Emerged, Reports at ISPOR Show
May 23rd 2020

MS Spending Spiked Over the Past Decade as Costly DMTs Emerged, Reports at ISPOR Show

Jared Kaltwasser
A new report shows just how much disease modifying therapies (DMTs) have changed the economic landscape of treating multiple sclerosis.
Study: Network Representation Learning Could Help Identify MS-Related Genes
May 17th 2020

Study: Network Representation Learning Could Help Identify MS-Related Genes

Jared Kaltwasser
Identifying the particular genes at play in multiple sclerosis (MS) could lead to a better understanding of the disease, and possibly better therapies for it. A new paper proposes network representation learning as the best method to identify those genes.
Study of Patients With Early MS Finds Universal Positivity to Epstein-Barr Antibodies
May 14th 2020

Study of Patients With Early MS Finds Universal Positivity to Epstein-Barr Antibodies

Jared Kaltwasser
A new analysis of patients with early multiple sclerosis (MS) suggests they universally carry antibodies for Epstein-Barr virus, a virus increasingly thought to be linked to MS.
Patients With MS Have Increased Risk for Cardiovascular Disease, Related Mortality
May 13th 2020

Patients With MS Have Increased Risk for Cardiovascular Disease, Related Mortality

Rachel Lutz
Patients with multiple sclerosis (MS) had a 3.5-fold increase in all-cause mortality and a 1.5-fold increase in cardiovascular disease mortality, compared with those without MS, even after controlling for traditional risk factors, and women were more at risk than men. Statins were linked with lowering the mortality risk.
Multidisciplinary, Holistic Approach Appears Effective in MS Treatment
May 13th 2020

Multidisciplinary, Holistic Approach Appears Effective in MS Treatment

Matthew Gavidia
Almost twice as many young women than men account for the 60% of Canadian adults with multiple sclerosis (MS) diagnosed between ages 20 and 49 years. Researchers developed an expert review of the most common comorbidities, as well as effective management styles available.
Patients With MS Should Not Stop DMT Because of Pandemic, Experts Say
May 1st 2020

Patients With MS Should Not Stop DMT Because of Pandemic, Experts Say

Gianna Melillo
In a commentary published in Multiple Sclerosis and Related Disorders, experts addressed common concerns individuals with multiple sclerosis (MS) might have when it comes to the coronavirus disease 2019 (COVID-19) pandemic and the use of disease-modifying therapies (DMTs).
Comorbidities Do Not Increase Odds of Multiple Sclerosis–Specific Hospitalizations
April 26th 2020

Comorbidities Do Not Increase Odds of Multiple Sclerosis–Specific Hospitalizations

Rachel Lutz
What relationship does the existence of comorbidities have on multiple sclerosis-related hospitalizations?
The Role of a Hospital Pharmacist in Managing Multiple Sclerosis
April 25th 2020

The Role of a Hospital Pharmacist in Managing Multiple Sclerosis

Rachel Lutz
Gathering the opinions of hospital pharmacists regarding the treatment of multiple sclerosis can be key for successful, multidisciplinary management of the disease, according to results from a focus group.
How Has COVID-19 Changed Multiple Sclerosis Care?
April 25th 2020

How Has COVID-19 Changed Multiple Sclerosis Care?

Gianna Melillo
Online systems, including telehealth, are imperative to maintaining optimal care for patients with multiple sclerosis (MS) during the coronavirus disease 2019 (COVID-19) pandemic, said June Halper, MSN, APN-C, MSCN, FAAN, chief executive officer, Consortium of Multiple Sclerosis Centers, in an interview with The American Journal of Managed Care® (AJMC®).
New Tools Needed to Assess Dysphagia in MS, Review Says
April 19th 2020

New Tools Needed to Assess Dysphagia in MS, Review Says

AJMC Staff
Difficulty swallowing affects about one-third of patients with multiple sclerosis.
Researchers Create, Validate Health Utilization Questionnaire for Multiple Sclerosis
April 9th 2020

Researchers Create, Validate Health Utilization Questionnaire for Multiple Sclerosis

Rachel Lutz
An efficient, concise patient questionnaire gathering health utilization information is effective for patients with multiple sclerosis, according to researchers who created one.
Physical Exercise Can Reduce Fatigue in Patients With MS, Review Finds
April 1st 2020

Physical Exercise Can Reduce Fatigue in Patients With MS, Review Finds

Gianna Melillo
Physical exercise significantly reduces fatigue in patients with multiple sclerosis (MS), according to a study published in BMC Neurology.
FDA Approves Ozanimod for Patients With RMS
March 26th 2020

FDA Approves Ozanimod for Patients With RMS

Gianna Melillo
The FDA approved Bristol Myers Squibb’s ozanimod (Zeposia) 0.92 mg as an oral treatment for relapsing forms of multiple sclerosis (RMS). Ozanimod can be used to treat clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Researchers Use Virtual Reality to Detect Early MS Balance Problems
March 24th 2020

Researchers Use Virtual Reality to Detect Early MS Balance Problems

Gianna Melillo
Researchers at the University of North Carolina School of Medicine found that falls simulated through virtual reality could enable early detection of balance problems in patients with multiple sclerosis (MS), according to a study published in PLoS One.
Synthetic MRI Can Be Useful in Calculating Myelin Volume Fraction, MS Study Says
March 23rd 2020

Synthetic MRI Can Be Useful in Calculating Myelin Volume Fraction, MS Study Says

Jared Kaltwasser
A new study compares synthetic magnetic resonance imaging (SyMRI) to other techniques for measuring myelin volume fraction in patients with multiple sclerosis (MS). The data indicate the technique is effective.
Common Preservative Found in Cheese May Shape MS Disease Course
March 18th 2020

Common Preservative Found in Cheese May Shape MS Disease Course

Gianna Melillo
Propionic acid, a short-chain fatty acid, influences the multiple sclerosis (MS) disease course by an immunomodulatory mechanism, according to a study published in Cell.
<1
...
456789101112
...
21>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo